<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        10-138-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KLACID XL 500MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Extended-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        59.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Abbott Laboratories" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Abbott Laboratories
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each Klacid XL tablet contains 500 mg of the active ingredient clarithromycin.<br />Klacid belongs to a group of medicines called macrolide antibiotics. Antibiotics stop the<br />growth of bacteria (bugs) which cause infections.<br />Klacid XL tablets are used to treat infections such as:<br />1. Upper respiratory tract infections for example, sinusitis, tonsillitis and pharyngitis.<br />2. Lower respiratory tract infections for example, acute and chronic bronchitis and<br />pneumonia.<br />3. Skin and soft tissue infections of mild to moderate severity for example, impetigo,<br />erysipelas, folliculitis, cellulitis, furunculosis, and infected wounds.<br />Klacid XL Tablets are used in adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XL Do not take Klacid XL tablets if you;<br />&bull; know that you are allergic to clarithromycin, other macrolide antibiotics such as<br />erythromycin or azithromycin, or any of the other ingredients in the tablets.<br />&bull; are taking medicines called ergot alkaloid tablets (e.g. ergotamine or dihydroergotamine)<br />or use ergotamine inhalers for migraine.<br />&bull; are taking medicines called terfenadine or astemizole (widely taken for hay fever or<br />allergies) or cisapride (for stomach problems) or pimozide (for mental health problems) as<br />combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult<br />your doctor for advice on alternative medicines.<br />&bull; are taking other medicines which are known to cause serious disturbances in heart<br />rhythm.<br />&bull; are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as<br />statins, used to lower levels of cholesterol (a type of fat) in the blood).</p><p>&bull; are taking oral midazolam (a sedative).<br />&bull; have abnormally low levels of potassium in your blood (hypokalaemia).<br />&bull; have severe liver disease with kidney disease.<br />&bull; or someone in your family has a history of heart rhythm disorders (ventricular cardiac<br />arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG,<br />electrical recording of the heart) called &quot;long QT syndrome&quot;.<br />&bull; are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina)<br />&bull; are taking colchicine (usually taken for gout)</p><p>Warnings and precautions<br />Talk to your doctor or pharmacist before taking Klacid XL tablets<br />&bull; if you have heart problems (e.g. heart disease, heart failure, an unusually slow heart<br />rate, or abnormally low levels of magnesium in the blood) (hypomagnesaemia))<br />&bull; if you have any liver or kidney problems<br />&bull; if you have, or are prone to, fungal infections (e.g. thrush)<br />&bull; if you are pregnant or breast feeding</p><p>Children<br />Klacid XL tablets are not suitable for use in children under 12 years of age.<br />Other medicines and Klacid XL tablets<br />You should not take Klacid XL tablets if you are taking any of the medicines listed in the<br />section above &ldquo;Do not take Klacid XL tablets if you;&rdquo;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines as your dose may need to be changed or you may need to have regular tests<br />performed:<br />&bull; digoxin, quinidine or disopyramide (for heart problems)<br />&bull; warfarin, or any other anticoagulant (for blood thinning)<br />&bull; carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)<br />&bull; atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins,<br />and used to lower levels of cholesterol (a type of fat) in the blood). Statins can cause<br />rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result<br />in kidney damage) and signs of myopathy (muscle pain or muscle weakness) should be<br />monitored.<br />&bull; nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose<br />levels)</p><p>&bull; gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)<br />&bull; theophylline (used in patients with breathing difficulties such as asthma)<br />&bull; triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)<br />&bull; cilostazol (for poor circulation)<br />&bull; methylprednisolone (a corticosteroid)<br />&bull; vinblastine (for treatment of cancer)<br />&bull; ciclosporin, sirolimus and tacrolimus (immune suppressants)<br />&bull; etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral<br />drugs used in the treatment of HIV)<br />&bull; rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of certain<br />bacterial infections)<br />&bull; tolterodine (for overactive bladder)</p><p>&bull; verapamil, amlodipine, diltiazem (for high blood pressure)<br />&bull; sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary<br />arterial hypertension (high blood pressure in the blood vessels of the lung))<br />&bull; St John&#39;s Wort (a herbal product used to treat depression)<br />&bull; quetiapine or other antipsychotic medicines<br />&bull; other macrolide medicines<br />&bull; lincomycin and clindamycin (lincosamides - a type of antibiotic)<br />Please tell your doctor if you are taking oral contraceptive pills and diarrhoea or vomiting<br />occurs, as you may need to take extra contraceptive precautions such as using a condom.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a<br />baby, ask your doctor or pharmacist before taking this medicine as the safety of Klacid XL<br />tablets in pregnancy and breast-feeding is not known.<br />Driving and Using Machines:<br />Klacid XL tablets may make you feel dizzy or drowsy. If they affect you in this way do not<br />drive, operate machinery or do anything that requires you to be alert.<br />Klacid XL tablets contain lactose<br />This medicine contains lactose, which is a type of sugar. If you have been told by your<br />doctor that you have an intolerance to some sugars, contact your doctor before taking<br />this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not give these tablets to children under 12 years. Your doctor will prescribe another<br />suitable medicine for your child.<br />Always take Klacid XL tablets exactly as your doctor has told you. Check with your doctor<br />or pharmacist if you are not sure.<br />The usual dose of Klacid XL tablets for adults and children over 12 years is one 500 mg<br />tablet once a day for 6 to 14 days.<br />Your doctor may increase the dose to two 500 mg tablets daily in severe infections. Klacid<br />XL tablets should be taken with food and must be swallowed whole and not chewed.<br />If you take more Klacid XL tablets than you should<br />If you accidentally take more Klacid XL tablets in one day than your doctor has told you to,<br />or if a child accidentally swallows some tablets, contact your doctor or nearest hospital<br />emergency department immediately. An overdose of Klacid XL tablets is likely to cause<br />vomiting and stomach pains.<br />If you forget to take Klacid XL tablets<br />If you forget to take a dose of Klacid XL tablets, take it as soon as you remember. Do not<br />take more tablets in one day than your doctor has told you to.<br />If you stop taking Klacid XL tablets<br />Do not stop taking Klacid XL tablets, even if you feel better. It is important to take the tablets<br />for as long as the doctor has told you to, otherwise the problem might come back.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Klacid XL tablets can cause side effects although not everybody gets<br />them. If you suffer from any of the following at any time during your treatment STOP<br />TAKING your tablets and contact your doctor immediately:<br />&bull; severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may</p><p>occur over two months after treatment with clarithromycin, in which case you should still<br />contact your doctor.<br />&bull; a rash, difficulty breathing, fainting or swelling of the face, tongue, lips, eyes and throat.<br />This is a sign that you may have developed an allergic reaction.<br />&bull; yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender<br />abdomen or loss of appetite. These are signs that your liver may have inflammation and<br />not be working properly.<br />&bull; severe skin reactions such as painful blistering of the skin, mouth, lips, eyes and<br />genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic<br />epidermal necrolysis).<br />&bull; a red, scaly rash with bumps under the skin and blisters (symptoms of exanthematous<br />pustulosis). The frequency of this side effect is not known (cannot be estimated from the<br />available data).<br />&bull; rare allergic skin reactions which cause severe illness with ulceration of the mouth, lips<br />and skin which causes severe illness with rash, fever and inflammation of internal organs<br />(DRESS).</p><p>&bull; muscle pain or weakness known as rhabdomyolysis (a condition which causes the<br />breakdown of muscle tissue which can result in kidney damage).<br />Other side effects<br />Common side effects (may affect up to 1 in 10 people) include;<br />&bull; difficulty sleeping<br />&bull; changes in sense of taste<br />&bull; headache<br />&bull; widening of blood vessels<br />&bull; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea<br />&bull; increased sweating<br />Uncommon side effects (may affect up to 1 in 100 people) include:<br />&bull; high temperature<br />&bull; swelling, redness or itchiness of the skin.<br />&bull; oral or vaginal &#39;thrush&#39; (a fungal infection)<br />&bull; inflammation of the stomach and intestines<br />&bull; decrease of the levels of blood platelets (blood platelets help stop bleeding)<br />&bull; decrease in white blood cells (leukopenia)<br />&bull; decrease in neutrophils (neutropenia)<br />&bull; stiffness<br />&bull; chills<br />&bull; increase of eosinophils (white blood cells involved in immunity)</p><p>&bull; exaggerated immune response to a foreign agent<br />&bull; lack or loss of appetite<br />&bull; anxiety, nervousness<br />&bull; drowsiness, tiredness, dizziness or shaking<br />&bull; involuntary muscle movements<br />&bull; vertigo<br />&bull; ringing in the ears or hearing loss<br />&bull; chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat<br />&bull; asthma: lung disease associated with tightening of air passages, making breathing<br />difficult<br />&bull; nose bleed</p><p>&bull; blood clot that causes sudden blockage in a lung artery (pulmonary embolism)<br />&bull; inflammation of the lining of the gullet (oesophagus) and lining of the stomach<br />&bull; anal pain<br />&bull; bloating, constipation, wind, burping<br />&bull; dry mouth<br />&bull; situation where the bile (fluid made by the liver and stored in the gallbladder) cannot<br />flow from the gallbladder to the duodenum (cholestasis)<br />&bull; inflammation of the skin characterized by the presence of the bullae which are filled<br />with fluid, itchy and painful rash<br />&bull; muscle spasms, muscle pain or loss of muscle tissue. If you suffer from myasthenia<br />gravis (a condition in which the muscles become weak and tire easily), clarithromycin may<br />worsen these symptoms.<br />&bull; raised abnormal kidney and liver function blood test and raised blood tests<br />&bull; feeling weak, tired and having no energy<br />Not known side effects (frequency cannot be estimated from the available data):<br />&bull; inflammation of the colon</p><p>&bull; bacterial infection of the outer layers of the skin<br />&bull; reduction in the level of certain blood cells (which can make infections more likely<br />or increase the risk of bruising or bleeding)<br />&bull; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or<br />panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or<br />over- excitement)<br />&bull; convulsion (fits)<br />&bull; paraesthesia, more commonly known as &#39;pins and needles&#39;<br />&bull; loss of taste or smell or inability to smell properly<br />&bull; type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)<br />&bull; loss of blood (haemorrhage)<br />&bull; inflammation of the pancreas<br />&bull; discolouration of the tongue or teeth<br />&bull; acne<br />&bull; change in the levels of products produced by the kidney, inflammation of the kidney or<br />an inability of the kidney to function properly (you may notice tiredness, swelling or<br />puffiness in the face, abdomen, thighs or ankles or problems with urination)<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible<br />side effects not listed in this leaflet. By reporting side effects you can help provide more<br />information on the safety of this medicine.</p><p>To report any side effect(s):<br />-National Pharmacovigilance Center (NPC)<br />o Fax: +966-1-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of sight and reach of children<br />&bull; Shelf Life: 36 Months<br />&bull; Do not use these tablets after their use-by (exp) date which is printed on the blister pack.<br />&bull; Store below 25&deg; C. Store in the original package.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each Klacid XL tablet contains 500 mg of the active ingredient clarithromycin.<br />The other ingredients are: citric acid, sodium alginate, sodium calcium alginate, lactose,<br />povidone, talc, stearic acid, magnesium stearate, hypromellose, polyethylene glycol,<br />titanium dioxide, sorbic acid, quinoline yellow (E104 aluminium lake).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Klacid XL tablets look like and contents of the pack
Klacid XL tablets are yellow, oval, modified release tablets.
Klacid XL tablets are available in blister packs containing 7 or 14 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />Abbott Laboratories Limited<br />Abbott House, Vanwall Business park<br />Vanwall Road,<br />Maidenhead Berkshire<br />SL6 4XE, UK<br />Manufacturer<br />Aesica Queenborough Limited,<br />North Road, Queenborough, Kent ME 11 5EL, UK<br />Packaged by<br />Riyadh Pharma<br />Medical and cosmetic<br />products Co. Ltd.<br />Riyadh - Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي كل قرص كلاسيد إكس-إل على 500 ملغم من المادة الفعالة كلاريثرومايسين التي تنتمي إلى مجموعة من المضادات الحيوية تسمى ماكروليد.</p><p dir="RTL">المضادات الحيوية تعمل على وقف نمو البكتيريا (الميكروبات) التي تسبب العدوى.</p><p dir="RTL"><strong>تستخدم أقراص كلاسيد إكس-إل لعلاج الالتهابات مثل:</strong></p><p dir="RTL">1. العدوى في الجهاز التنفسي العلوي مثل التهاب الجيوب الأنفية، التهاب اللوزتين، والتهاب البلعوم.</p><p dir="RTL">2. العدوى في الجهاز التنفسي السفلي مثل التهاب الشعب الحاد أو المزمن والتهاب الرئة.</p><p dir="RTL">3. العدوى الخفيفة أو متوسطة الخطورة في الجلد والأنسجة الرخوة، مثل الحصف، الحمرة، التهاب الأجربة، والتهاب النسيج الخلوي الرخو تحت الجلد, و الدمامل، والجروح المتقيحة. &nbsp;</p><p dir="RTL">أقراص كلاسيد إكس-إل مخصصة للبالغين والأطفال أكبر من سن 12 عام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال كلاسيد إكس-إل إذا كنت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرف أن لديك حساسية من كلاريثرومايسين، والمضادات الحيوية الأخرى التي تنتمي إلى مجموعة ماكروليد مثل الاريثروميسين أو أزيثروميسين، أو أي من المكونات الأخرى في أقراص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى أقراص قلويدات الأرجوت( مثل الإرجوتامين أو دايهيدروإرجوتامين) أو تستعمل بخاخات&nbsp; للاستنشاق لعلاج الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أدوية ترفينادين أو أستيميزول (تؤخذ على نطاق واسع لحمى الكلأ أو الحساسية) أو سيسابريد (لاضطرابات المعدة) أو بيموزيد (لمشاكل الصحة النفسية) حيث أن تناول هذه الأدوية معا يمكن أن يسبب أحيانا اضطرابات خطيرة في انتظام ضربات القلب. استشر طبيبك للحصول على المشورة بشأن تناول الأدوية البديلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناولون أدوية أخرى من المعروف أنها تسبب اضطرابات خطيرة في انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول لوفاستاتين أو سيمفاستاتين (مثبطات&nbsp;الإنزيم HMG-CoA المعروف باسم الستاتينات، وتستخدم لخفض مستويات الكولسترول (نوع من الدهون) في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول ميدازولام عن طريق الفم (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من انخفاض مستويات البوتاسيوم في الدم بشكل غير طبيعي (نقص بوتاسيوم الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصاب بأمراض كبدية شديدة مع أمراض الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شخص ما في عائلتك لديه تاريخ من اضطرابات ضربات القلب (عدم انتظام ضربات القلب البطيني، بما في ذلك حالة تورساد دي بوانت) أو شذوذ مخطط كهربائية القلب(خلل في رسم القلب والتسجيل الكهربائي للقلب) يسمى &quot;متلازمة&nbsp;كيو تي الطويلة &quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى تيكاجريلور أو رانولازين (للنوبة القلبية أو ألم في الصدر أو الذبحة الصدرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الكولشيسين (عادة ما يؤخذ للنقرس)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL"><strong>تحدث مع طبيبك أو الصيدلي قبل تناول أقراص كلاسيد إكس -إل في الحالات التالية.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب (مثل أمراض القلب أو قصور القلب أو بطئ في معدل ضربات القلب بشكل غير عادي أو انخفاض غير طبيعي لمستويات المغنيسيوم في الدم (نقص مغنيسيوم الدم))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في الكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك، أو عرضة للعدوى الفطرية (على سبيل المثال القلاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملا أو في مرحلة الرضاعة الطبيعية.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL"><strong>لا يُنصح باستخدام أقراص كلاسيد إكس إل مع الأطفال الذين تقل أعمارهم عن 12 عامًا.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام مع الأدوية الأخرى:</strong></p><p dir="RTL">ينبغي <strong>ألا</strong> تتناول أقراص كلاسيد إكس إل إن كنت تتناول أيًا من الأدوية المبينة في القسم المذكور أعلاه &quot;لا تتناول أقراص كلاسيد إكس إل إن كنت&quot;</p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تناولت، أو قد تتناولت مؤخرا أي أدوية أخرى أو قد تتناول مستقبلا أي أدوية أخرى، حيث أن قد تحتاج إلى تغيير جرعة كلاسيد إكس-إل التي تتناولها أو ينبغي عليك إجراء بعض الفحوصات بانتظام:</p><p dir="RTL">&bull; ديجوكسين أو كويندين أو ديزوبراميد (لعلاج مشكلات القلب).<br />&bull; وارفارین أو أي من مضادات التجلط الأخرى (لإسالة الدم)<br />&bull; كاربامازیبین، ڤالبروات، فینوباربیتال أو فیناتون (أدویة الصرع).</p><p dir="RTL">&bull; &nbsp; أتورفاستاتين، رسيوفاستاتين (مثبطات&nbsp;الإنزيم HMG-CoA المعروف على نحو شائع باسم الستاتين، والتي تستخدم لخفض مستويات الكولسترول (نوع من الدهون في الدم). الستاتينات يمكنها&nbsp; أن تسبب انحلال العضلات المخططـة الهيكليـة (الحالة التي يحدث فيها انهيار الأنسجة العضلية والتي يمكن أن تؤدي إلى تلف الكلى)ومن ثم ينبغي مراقبة أعراض الاعتلال العضلي (آلام العضلات أو ضعف العضلات) .</p><p dir="RTL">&bull; ناتيجلينيدين، بيوجليتازون، ريباجلينيد، روزيجليتازون أو الأنسولين (التي تستخدم لخفض مستويات الجلوكوز في الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; جليكلازيد أو جليميبيريد (ادوية السلفونيل يوريا المستخدمة في علاج النوع الثاني من مرض السكري)</p><p dir="RTL">&bull;&nbsp;&nbsp; ثيوفيللين (المستخدم في علاج المرضى المصابین بصعوبات تنفسیة مثل الربو).</p><p dir="RTL">&bull; ترایازولام، البرازولام، میدازولام للغشاء المخاطي الفموي أو للاستخدام عن طریق الورید (مھدئ).</p><p dir="RTL">&nbsp;&bull;سیلوستازول (لعلاج قصور الدورة الدمویة).</p><p dir="RTL">&bull; میثیل بردنیزولون (كورتیكوستیروید).</p><p dir="RTL">&bull; ڤینبلاستین (لعلاج السرطان).</p><p dir="RTL">&bull; سیكلوسبورین، سیرولیمیس، تاكرولیمیس (مثبطات المناعة).</p><p dir="RTL">&bull;&nbsp; إترافيرين، إيفافيرنز، نيفيرابين، ريتونافير، زيدوفودين، أتازانافير، ساكينافير (الأدوية المضادة للفيروسات المستخدمة في علاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&bull; ریفابیوتین، ریفامبیسین، ریفابنتین، فلوكانازول، أیتراكونازول ( تسُتخدم في علاج بعض الالتھابات البكتیریة).</p><p dir="RTL">&bull; تولتیرودین (لعلاج فرط نشاط المثانة).</p><p dir="RTL">&bull; فیرابامیل، أملودیبین، دیلتیازیم (لارتفاع ضغط الدم).</p><p dir="RTL">&bull; &nbsp; سيلدينافيل، فاردينافيل، تادالافيل (علاج العجز الجنسي عند الذكور البالغين أو للاستخدام في ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الأوعية الدموية في الرئة).</p><p dir="RTL">&bull; عشبة سانت جون (منتج عشبي یسُتخدم لعلاج الاكتئاب).</p><p dir="RTL">&bull; كیتیابین أو الأدویة الأخرى المضادة للذھان.</p><p dir="RTL">&bull; الأدویة الماكرولیدیة الأخرى</p><p dir="RTL">&bull; لینكومیسین وكلیندامایسین (لینكوسامیدس - نوع من المضادات الحیویة)</p><p dir="RTL">يرجى إبلاغ طبيبك إن كنتِ تتناولين حبوب منع الحمل وفي حالة حدوث الإسهال أو القيء، لأنكِ قد تحتاجين لاحتياطات إضافية لمنع الحمل مثل استخدام واقٍ ذكري عند ممارسة العلاقة الحميمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة:<br />إذا كنت حاملا،ً أو ترضعین طفلك رضاعة طبیعیة أو تعتقدین أنك قد تكونین حاملا،ً أو تخططین للحمل، فیجب استشارة طبیبكِ أو<br />الصیدلي قبل تناول ھذا الدواء حیث إن سلامة استخدام أقراص كلاسید إكس-إل في الحمل والرضاعة غیر معروفة.</p><p dir="RTL">القیادة واستخدام الآلات:<br />أقراص كلاسید إكس-إل قد تجعلك تشعر بالدوار أو النعاس. إذا كان ھذا الدواء یؤثر علیك بھذه الطریقة، فیجب عدم القیادة أو تشغیل<br />الآلات أو القیام بعمل یتطلب منك ان تكون في حالة یقظة.</p><p dir="RTL">تحتوي أقراص كلاسید إكس إل على لاكتوز<br />یحتوي ھذا الدواء على لاكتوز، وھو نوع من السكر. إذا أخبرك طبیبك بأنك لا تتحمل بعض السكریات، فتواصل مع طبیبك قبل<br />تناول ھذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تعطِ ھذه الأقراص للأطفال دون سن ۱۲ عاماً. وسوف یصف الطبیب الدواء المناسب لطفلك.<br />یجب تناول جرعة كلاسید إكس-إل كما یصفھا الطبیب. یجب علیك أن تستشیر طبیبك أو الصیدلي إذا كنت غیر متأكد من الجرعة<br />المقررة لك.<br />الجرعة المعتادة من أقراص كلاسید إكس-إل للبالغین والأطفال فوق 12 سنة ھي 500 ملغم مرة واحدة في الیوم لمدة 6 أیام إلى<br />14 یوم اً. وقد یحتاج طبیبك لزیادة الجرعة إلى قرصین 500 ملغم یومیاً في العدوي الشدیدة. یجب ابتلاع أقراص كلاسید إكس-إل<br />كاملة مع الطعام ولا ینبغي مضغھا.</p><p dir="RTL">إذا تناولت جرعة زائدة من أقراص كلاسید إكس-إل:<br />إذا تناولت أكثر من الجرعة المقررة من أقراص كلاسید إكس-إل بطریق الخطأ في یوم واحد، أو إذا ابتلع الطفل بعض الأقراص<br />بطریق الخطأ، فاتصل بالطبیب أو بأقرب مستشفى أو قسم طوارئ عَلى الفور حیث قد تتسبب الجرعة الزائدة من أقراص كلاسید<br />إكس-إل في التقیؤ وآلام في المعدة.<br />إذا نسیت أن تتناول أقراص كلاسید إكس-إل:<br />إذا نسیت أن تتناول جرعة من أقراص كلاسید إكس-إل، فیمكنك تناولھا في أقرب وقت تتذكرھا. لا تتناول أكثر من الجرعة التي<br />وصفھا لك الطبیب في یوم واحد.</p><p dir="RTL">التوقف عن تناول كلاسید إكس-إل:<br />لا تتوقف عن تناول أقراص كلاسید إكس-إل، حتى لو كنت تشعر بتحسن ومن المھم أن تتناول الأقراص على مدار المدة التي حددھا<br />لك الطبیب، وإلا فإن المرض قد یعود مرة أخرى.<br />إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء، فاسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة، یمكن أن تسبب أقراص كلاسید إكس-إل بعض الآثار الجانبیة على الرغم من عدم حدوث ذلك لكل الأشخاص.<br />إذا كنت تعاني من أي من الأعراض التالیة في أي وقت أثناء العلاج، فیجب وقف تناول الأقراص والاتصال بالطبیب على الفور.</p><p dir="RTL">&bull; الإسهال الشديد أو الإسهال لفترات طويلة، والذي قد يكون مختلط به دم أو مخاط. قد يحدث الإسهال على مدى أكثر من شهرين &nbsp;بعد العلاج بالكلاريثرومايسين،وإذا حدث ذلك ففي هذه الحالة يجب الاتصال بالطبيب.</p><p dir="RTL">&bull; طفح جلدي، أو صعوبة التنفس، أو الإغماء، أو تورم الوجھ أو اللسان أو الشفتین أو العینین أو الحلق. وھذه علامة على<br />احتمال إصابتك برد فعل تحسسي.</p><p dir="RTL">&bull; اصفرار الجلد (اليرقان)، أو تهيج الجلد، أو البراز فاتح اللون، أو البول غامق اللون، أو أيلام البطن عند لمسها، أو فقدان الشهية. تلك علامات أن كبدك قد يكون مصابًا بالالتهاب وأنه قد لا يؤدي وظيفته بشكل سليم.</p><p dir="RTL">&bull; تفاعلات جلدية شديدة مثل تقرحات مؤلمة في الجلد والفم والعينين والشفتين والأعضاء التناسلية، (أعراض الحساسية رد فعل نادر يسمى متلازمة ستيفنز جونسون / تقشر الأنسجة المتموته البشورية التسممي).</p><p dir="RTL">&bull; طفح جلدي أحمر ومتقشر، مع تحادیب تحت الجلد وبثور (أعراض البثار الطفحي). معدّل تكرار ھذا الأثر الجانبي مجھول<br />(أي لا یمكن تقدیر ه من خلال البیانات المتاحة).</p><p dir="RTL">&bull; تفاعلات حساسیة حادة بالجلد تسبب مرض اً شدید اً مصحوب اً بتقرّح الفم والشفتین والجلد، مما یسبب مرض اً شدید ا یًصاحبھ طفح&nbsp;&nbsp;جلدي وحمى والتھاب الأعضاء الداخلیة (متلازمة DRESS)</p><p dir="RTL">&bull; ألم أو ضعف في العضلات یعُرف باسم انحلال الربیدات (وھي حالة تتسبب في انھیار الأنسجة العضلیة والتي یمكن أن تؤدي<br />إلى تلف الكلى).</p><p dir="RTL">آثار جانبیة أخرى</p><p dir="RTL">الآثار الجانبیة الشائعة (قد تؤثر على ما یصل إلى 1 من أصل 10 أشخاص) وتشمل:</p><p dir="RTL">&bull; صعوبة النوم<br />&bull; التغیرات في حاسة التذوق<br />&bull; الصداع<br />&bull; اتساع الأوعیة الدمویة<br />&bull; مشاكل في المعدة مثل الشعور بالإعیاء، والتقیؤ، وآلام في المعدة، وعسر الھضم، والإسھال<br />&bull; زیادة التعرق<br />الآثار الجانبیة غیر الشائعة (قد تؤثر على ما یصل إلى 1 من أصل 100 شخص) وتشمل:<br />&bull; ارتفاع درجة الحرارة<br />&bull; تورم، احمرار أو حكة في الجلد<br />&bull; عدوى فطریة بالفم أو المھبل (القلاع)<br />&bull; التھاب المعدة والأمعاء<br />&bull; انخفاض مستویات الصفائح الدمویة (الصفائح الدمویة تساعد على وقف النزیف)<br />&bull; انخفاض في عدد خلایا الدم البیضاء (نقص الكریات البیض)<br />&bull; انخفاض شاذ في تعداد الكریات البیض المعتدلة (نقص العدلات)<br />&bull; التصلب</p><p dir="RTL">&bull; القشعریرة<br />&bull; زیادة الحمضات (ارتفاع مستوى الكریات البیضاء الحمِضة المساعدة في المناعة)<br />&bull; زیادة الاستجابة المناعیة للأجسام الغریبة.<br />&bull; نقص الشھیة أو فقدانھا<br />&bull; القلق والعصبیة<br />&bull; نعاس، تعب، دوخة أو رعشة<br />&bull; حركات لا إرادیة بالعضلات<br />&bull; الدوار<br />&bull; رنین في الأذنین أو فقدان السمع<br />&bull; ألم في الصدر أو تغیرات في إیقاع نبضالقلب مثل الخفقان أو عدم انتظام ضربات القلب<br />&bull; الربو: أمراض الرئة المرتبطة بضیق الممرات الھوائیة، مما یجعل التنفس صعب اً<br />&bull; نزیف الأنف<br />&bull; تجلط الدم الذي یسبب انسداد اً مفاجئ اً في شریان الرئة (الانصمام الرئوي)<br />&bull; التھاب بطانة المريء وبطانة المعدة<br />&bull; ألم بالشرج<br />&bull; الانتفاخ والإمساك وخروج الغازات من البطن والتجشؤ<br />&bull; جفاف الفم</p><p dir="RTL">&bull;ركود الصفراء (السوائل التي يفرزها الكبد وتخزن في المرارة) لا يمكن أن تتدفق من المرارة إلى الاثني عشر (ركود صفراوي)</p><p dir="RTL">&bull; التھاب الجلد الذي یتمیز بوجود فقاعات ملیئة بالسوائل، وبالطفح الجلدي المؤلم والمثیر للحكة.<br />&bull; تشنجات العضلات، آلام في العضلات أو فقدان الأنسجة العضلیة. إذا كنت تعاني من الوھن العضلي الوبیل (وھي حالة تصبح<br />فیھا العضلات ضعیفة ویصیبھا التعب بسھولة)، فقد یؤدي كلاریثرومایسین إلى تفاقم ھذه الأعراض<br />&bull; نتائج مرتفعة وغیر طبیعیة لاختبارات الدم لوظائف الكلى والكبد وغیرھا من اختبارات الدم<br />&bull; الشعور بالضعف والتعب وفقدان الطاقة<br />الآثار الجانبیة غیر المعروفة (لا یمكن تقدیر معدل تكرارھا من البیانات المتاحة):<br />&bull; التھاب القولون<br />&bull; عدوى بكتیریة في الطبقات الخارجیة من الجلد</p><p dir="RTL">&bull; انخفاض مستوى بعض خلایا الدم (التي یمكن أن تزید من احتمالیة الإصابة بالعدوى أو تزید من خطر الكدمات أو النزیف)</p><p dir="RTL">&bull;الارتباك، وفقدان الاتجاهات، والهلوسة (رؤية أشياء غير حقيقية)، وتغيير الشعور بالواقع أو الفزع، والاكتئاب، والأحلام غير الطبيعية أو الكوابيس والهوس (الشعور بالانتفاخ أو الإفراط في الاستثارة)</p><p dir="RTL">&bull; التشنج (نوبات)<br />&bull; التنمیل، وغالب اً ما یتم الشعور بھ على ھیئة إحساس بوخذ الدبابیس والإبر<br />&bull; فقدان حاسة التذوق أو الشم أو عدم القدرة على الشم بشكل صحیح<br />&bull; نوع من اضطراب ضربات القلب (تورساد دي بوانت، تسرع القلب البطیني)<br />&bull; فقدان الدم (النزف)<br />&bull; التھاب البنكریاس<br />&bull; تغیر لون اللسان أو الأسنان<br />&bull; حب الشباب</p><p dir="RTL">&bull; &nbsp; تغير في مستويات إفرازات التي تنتجها الكلى، التهاب الكلى أو عدم قدرة الكلى على العمل بشكل صحيح (قد تلاحظ التعب، التورم أو الانتفاخ في الوجه والبطن والفخذين او الكاحلين أو مشكلات في التبول)</p><p dir="RTL">إذا اصبت باي من هذه الأعراض الجانبيه, فأبلغ&nbsp;الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فترة الصلاحية: 36 شهراً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذه الأقراص بعد تاريخ انتهاء الصلاحية كما هو مطبوع على الشريط والعلبة الخارجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 25 درجة مئوية. ويجب أن تحفظ في عبوتها الأصلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتوى عبوة كلاسيد إكس-إل أقراص.</strong></p><p dir="RTL">يحتوي كل قرص كلاسيد إكس-إل على المادة الفعالة كلاريثروميسين بتركيز 500 ملغم.</p><p>الصواغات الأخرى هي: حمض الستريك، ألجينات الصوديوم، ألجينات الصوديوم الكالسيوم، اللاكتوز، البوفيدون، التلك، حامض ستياريك، ستيرات المغنيسيوم، هايبروميلوز، البولي ايثيلين جليكول، ثاني أكسيد التيتانيوم، حمض السوربيك، كينولين أصفر (E104).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل كلاسيد إكس-إل ومحتويات العلبة؟</strong></p><p dir="RTL">أقراص كلاسيد إكس-إل 500 ملغم عبارة عن أقراص صفراء، بيضاوية ممتدة المفعول.</p><p dir="RTL">تتوافر أقراص كلاسيد إكس-إل 500 ملغم في شرائط تحتوي على 7 و14 قرص.</p><p dir="RTL">قد لا تتوفر كافة العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL">أبوب لابوراتوريز ليميتد،</p><p dir="RTL">أبوت هاوس، فانوال بزنس بارك،&nbsp;</p><p dir="RTL">فانوال رود، ميدينهيد بيركشر، إس إل 6 4 إكس إي، المملكة المتحدة</p><p dir="RTL"><strong>المصنع:</strong></p><p dir="RTL">إيسيكا كوينبوروغ ليميتد،</p><p>نورث رود كوينبوروغ، كينت إم إي 11 5 إي إل - المملكة المتحدة</p><p>تم التغلیف في:<br />مصنع الریاض فارما للصناعات الدوائیة ومستحضرات التجمیل<br />الریاض، المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Klacid® XL 500 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One table contains 500 mg clarithromycin.
Excipients with known effect: lactose and sodium
Each tablet contains 115 mg lactose and 15.3 mg sodium
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A yellow, ovaloid tablet containing 500mg clarithromycin in a modifiedrelease
preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Consideration should be given to official guidance on the appropriate use of<br />antibacterial agents.<br />Klacid XL 500 mg Tablets are indicated in adults and children 12 years and<br />older.<br />Klacid XL 500 mg Tablets are indicated for treatment of infections caused by<br />susceptible organisms. Indications include:<br />Lower respiratory tract infections for example, acute and chronic bronchitis,<br />and pneumonia (see section 4.4 and 5.1 regarding Sensitivity Testing).<br />Upper respiratory tract infections for example, sinusitis and pharyngitis.<br />Klacid XL 500 mg Tablets are also indicated in skin and soft tissue infections<br />of mild to moderate severity, for example folliculitis, cellulitis and erysipelas<br />(see section 4.4 and 5.1 regarding Sensitivity Testing).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults: The usual recommended dosage of Klacid XL 500 mg Tablets in<br />adults is one 500mg modified-release tablet daily to be taken with food. In<br />more severe infections, the dosage can be increased to two 500mg modifiedrelease<br />tablets daily. The usual duration of treatment is 6 to 14 days.</p><p>Children older than 12 years: As for adults.<br />Do not crush or chew Klacid XL 500 mg Tablets.<br />Klacid XL 500 mg Tablets should not be used in patients with significant renal<br />impairment (creatinine clearance less than 30 ml/min), as appropriate<br />clarithromycin dosage reduction is not possible when administering this<br />product. Clarithromycin immediate release tablets may be utilized in this<br />patient population (see section 4.3). The dosage of clarithromycin should be<br />reduced by one-half, i.e. 250 mg once daily, or 250 mg twice daily in more<br />severe infections. Treatment should not be continued beyond 14 days in these<br />patients. For patients with moderate renal function (creatinine clearance 30 to<br />60 ml/min), a 50% dosage reduction should be implemented resulting in a<br />maximum dose of one Klacid XL 500 mg Tablet per day.<br />Children younger than 12 years: Use of Klacid XL 500 mg Tablets are not<br />recommended for children younger than 12 years. Clinical trials have been<br />conducted using clarithromycin peadiatric suspension in children 6 months to<br />12 years of age. Therefore, children under 12 years of age should use<br />clarithromycin peadiatric suspension (granules for oral suspension).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to macrolide antibiotic drugs or to any of the excipients listed
in section 6.1.
In the case of Klacid XL 500 mg Tablets, as the dose cannot be reduced from
500mg daily, Klacid 500 mg Tablets are contraindicated in patients with
creatinine clearance less than 30 mL/min. All other formulations may be used
in this patient population.
Concomitant administration of clarithromycin and ergot alkaloids (e.g.
ergotamine or dihydroergotamine) is contraindicated, as this may result in
ergot toxicity (see section 4.5).
Concomitant administration of clarithromycin and oral midazolam is
contraindicated (see section 4.5).
Concomitant administration of clarithromycin and any of the following drugs
is contraindicated: astemizole, cisapride, pimozide and terfenadine as this
may result in QT prolongation and cardiac arrhythmias, including ventricular
tachycardia, ventricular fibrillation, and torsades de pointes (see section 4.5).
Clarithromycin should not be given to patients with history of QT
prolongation (congenital or documented acquired QT prolongation) or
ventricular cardiac arrhythmia, including torsades de pointes (see sections 4.4
and 4.5).
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Clarithromycin should not be used concomitantly with HMG-CoA reductase
inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or
simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.
(see section 4.5).
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in
patients taking colchicine (see sections 4.4 and 4.5).
Clarithromycin should not be given to patients with hypokalaemia (risk of
prolongation of QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic
failure in combination with renal impairment.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without<br />carefully weighing the benefits against risk; particularly during the first three<br />months of pregnancy (see section 4.6).<br />Clarithromycin is principally metabolised by the liver. Therefore, caution<br />should be exercised in administering this antibiotic to patients with impaired<br />hepatic function.<br />Caution should also be exercised when administering clarithromycin to<br />patients with moderate to severe renal impairment (see section 4.2).<br />Hepatic dysfunction, including increased liver enzymes, and hepatocellular<br />and/or cholestatic hepatitis, with or without jaundice, has been reported with<br />clarithromycin. This hepatic dysfunction may be severe and is usually<br />reversible. Cases of fatal hepatic failure (see section 4.8) have been reported.<br />Some patients may have had pre-existing hepatic disease or may have been<br />taking other hepatotoxic medicinal products. Patients should be advised to<br />stop treatment and contact their doctor if signs and symptoms of hepatic<br />disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender<br />abdomen.</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial<br />agents, including macrolides, and may range in severity from mild to lifethreatening.<br />Clostridium difficile- associated diarrhoea (CDAD) has been<br />reported with use of nearly all antibacterial agents including clarithromycin,<br />and may range in severity from mild diarrhoea to fatal colitis. Treatment with<br />antibacterial agents alters the normal flora of the colon, which may lead to<br />overgrowth of C. difficile. CDAD must be considered in all patients who<br />present with diarrhoea following antibiotic use. Careful medical history is</p><p>necessary since CDAD has been reported to occur over two months after the<br />administration of antibacterial agents. Therefore, discontinuation of<br />clarithromycin therapy should be considered regardless of the indication.<br />Microbial testing should be performed and adequate treatment initiated. Drugs<br />inhibiting peristalsis should be avoided.<br />There have been post-marketing reports of colchicine toxicity with<br />concomitant use of clarithromycin and colchicine, especially in the elderly,<br />some of which occurred in patients with renal insufficiency. Deaths have been<br />reported in some such patients (see section 4.5). Concomitant administration<br />of clarithromycin and colchicine is contraindicated(see section 4.3).<br />Caution is advised regarding concomitant administration of clarithromycin<br />and triazolobenzodiazepines, such as triazolam, and intravenous or<br />oromucosal midazolam (see section 4.5).</p><p>Cardiovascular Events:<br />Prolonged cardiac repolarisation and QT interval, imparting a risk of<br />developing cardiac arrhythmia and torsades de pointes, have been seen in<br />treatment with macrolides including clarithromycin (see section 4.8).<br />Therefore, as the following situations may lead to an increased risk for<br />ventricular arrhythmias (including torsades de pointes), clarithromycin should<br />be used with caution in the following patients;<br />&bull; Patients with coronary artery disease, severe cardiac insufficiency,<br />conduction disturbances or clinically relevant bradycardia<br />&bull; Patients with electrolyte disturbances such as hypomagnesaemia.<br />Clarithromycin must not be given to patients with hypokalaemia (see<br />section 4.3).<br />&bull; Patients concomitantly taking other medicinal products associated with<br />QT prolongation (see section 4.5).<br />&bull; Concomitant administration of clarithromycin with astemizole,<br />cisapride, pimozide and terfenadine is contraindicated (see section 4.3).<br />Clarithromycin must not be used in patients with congenital or<br />documented acquired QT prolongation or history of ventricular<br />arrhythmia (see section 4.3).</p><p>Epidemiological studies investigating the risk of adverse cardiovascular<br />outcomes with macrolides have shown variable results. Some observational<br />studies have identified a rare short-term risk of arrhythmia, myocardial<br />infarction and cardiovascular mortality associated with macrolides including<br />clarithromycin. Consideration of these findings should be balanced with<br />treatment benefits when prescribing clarithromycin.<br />Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae<br />to macrolides, it is important that sensitivity testing be performed when<br />prescribing clarithromycin for community-acquired pneumonia. In hospitalacquired<br />pneumonia, clarithromycin should be used in combination with<br />additional appropriate antibiotics.</p><p>Skin and soft tissue infections of mild to moderate severity: These infections<br />are most often caused by Staphylococcus aureus and Streptococcus pyogenes,<br />both of which may be resistant to macrolides. Therefore, it is important that<br />sensitivity testing be performed. In cases where beta&ndash;lactam antibiotics cannot<br />be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug<br />of first choice. Currently, macrolides are only considered to play a role in<br />some skin and soft tissue infections, such as those caused by Corynebacterium<br />minutissimum, acne vulgaris, and erysipelas and in situations where penicillin<br />treatment cannot be used.<br />In the event of severe acute hypersensitivity reactions, such as anaphylaxis,<br />severe cutaneous adverse reactions (SCAR) (e.g. Acute generalised<br />exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome, toxic<br />epidermal necrolysis and drug rash with eosinophilia and systemic symptoms<br />(DRESS)), clarithromycin therapy should be discontinued immediately and<br />appropriate treatment should be urgently initiated.</p><p>Clarithromycin should be used with caution when administered concurrently<br />with medications that induce the cytochrome CYP3A4 enzyme (see section<br />4.5).<br />HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin<br />with lovastatin or simvastatin is contraindicated (see section 4.3). Caution<br />should be exercised when prescribing clarithromycin with other statins.<br />Rhabdomyolysis has been reported in patients taking clarithromycin and<br />statins. Patients should be monitored for signs and symptoms of myopathy.<br />In situations where the concomitant use of clarithromycin with statins cannot<br />be avoided, it is recommended to prescribe the lowest registered dose of the<br />statin. Use of a statin that is not dependent on CYP3A metabolism (e.g.<br />fluvastatin) can be considered (see section 4.5).<br />Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin<br />and oral hypoglycaemic agents (such as sulphonylurias) and/or insulin can<br />result in significant hypoglycaemia. Careful monitoring of glucose is<br />recommended (see section 4.5).</p><p>Oral anticoagulants: There is a risk of serious haemorrhage and significant<br />elevations in International Normalized Ratio (INR) and prothrombin time<br />when clarithromycin is co-administered with warfarin (see section 4.5). INR<br />and prothrombin times should be frequently monitored while patients are<br />receiving clarithromycin and oral anticoagulants concurrently.<br />Long-term use may, as with other antibiotics, result in colonisation with<br />increased numbers of non-susceptible bacteria and fungi. If superinfections<br />occur, appropriate therapy should be instituted.</p><p>Attention should also be paid to the possibility of cross resistance between<br />clarithromycin and other macrolide drugs, as well as lincomycin and<br />clindamycin.<br />Excipients<br />Klacid Modified Release contains lactose. Patients with rare hereditary<br />problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose<br />malabsorption should not take these medicines<br />Klacid XL 500mg Tablets contain 15.3 mg sodium per tablet. If patients<br />receive two Modified Release tablets once daily, the resulting sodium amount<br />(in total 30.6 mg per dose) should be taken into consideration for patients on a<br />controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of the following drugs is strictly contraindicated due to the<br />potential for severe drug interaction effects:<br />Cisapride, pimozide, astemizole and terfenadine:<br />Elevated cisapride levels have been reported in patients receiving<br />clarithromycin and cisapride concomitantly. This may result in QT<br />prolongation and cardiac arrhythmias including ventricular tachycardia,<br />ventricular fibrillation and torsades de pointes. Similar effects have been<br />observed in patients taking clarithromycin and pimozide concomitantly (see<br />section 4.3).<br />Macrolides have been reported to alter the metabolism of terfenadine resulting<br />in increased levels of terfenadine which has occasionally been associated with<br />cardiac arrhythmias, such as QT prolongation, ventricular tachycardia,<br />ventricular fibrillation and torsades de pointes (see section 4.3). In one study<br />in 14 healthy volunteers, the concomitant administration of clarithromycin and<br />terfenadine resulted in 2- to 3-fold increase in the serum level of the acid<br />metabolite of terfenadine and in prolongation of the QT interval which did not<br />lead to any clinically detectable effect. Similar effects have been observed<br />with concomitant administration of astemizole and other macrolides.</p><p>Ergot alkaloids:<br />Post-marketing reports indicate that co-administration of clarithromycin with<br />ergotamine or dihydroergotamine has been associated with acute ergot toxicity<br />characterized by vasospasm, and ischaemia of the extremities and other tissues<br />including the central nervous system. Concomitant administration of<br />clarithromycin and ergot alkaloids is contraindicated (see section 4.3).<br />Oral Midazolam<br />When midazolam was co-administered with clarithromycin tablets (500 mg<br />twice daily), midazolam AUC was increased 7-fold after oral administration of<br />midazolam. Concomitant administration of oral midazolam and clarithromycin<br />is contraindicated(see section 4.3).</p><p>HMG-CoA Reductase Inhibitors (statins)<br />Concomitant use of clarithromycin with lovastatin or simvastatin is<br />contraindicated (see 4.3) as these statins are extensively metabolized by<br />CYP3A4 and concomitant treatment with clarithromycin increases their<br />plasma concentration, which increases the risk of myopathy, including<br />rhabdomyolysis. Reports of rhabdomyolysis have been received for patients<br />taking clarithromycin concomitantly with these statins. If treatment with<br />clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must<br />be suspended during the course of treatment.<br />Caution should be exercised when prescribing clarithromycin with statins. In<br />situations where the concomitant use of clarithromycin with statins cannot be<br />avoided, it is recommended to prescribe the lowest registered dose of the<br />statin. Use of a statin that is not dependent on CYP3A metabolism<br />(e.g.fluvastatin) can be considered. Patients should be monitored for signs and<br />symptoms of myopathy.</p><p>Effects of Other Medicinal Products on Clarithromycin<br />Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine,<br />phenobarbital, St John&rsquo;s wort) may induce the metabolism of clarithromycin.<br />This may result in sub-therapeutic levels of clarithromycin leading to reduced<br />efficacy. Furthermore, it might be necessary to monitor the plasma levels of<br />the CYP3A inducer, which could be increased owing to the inhibition of<br />CYP3A by clarithromycin (see also the relevant product information for the<br />CYP3A4 inducer administered). Concomitant administration of rifabutin and<br />clarithromycin resulted in an increase in rifabutin, and decrease in<br />clarithromycin serum levels together with an increased risk of uveitis.<br />The following drugs are known or suspected to affect circulating<br />concentrations of clarithromycin; clarithromycin dosage adjustment or<br />consideration of alternative treatments may be required.</p><p>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine<br />Strong inducers of the cytochrome P450 metabolism system such as efavirenz,<br />nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the<br />metabolism of clarithromycin and thus lower the plasma levels of<br />clarithromycin, while increasing those of 14-OH-clarithromycin, a metabolite<br />that is also microbiologically active. Since the microbiological activities of<br />clarithromycin and 14-OH-clarithromycin are different for different bacteria,<br />the intended therapeutic effect could be impaired during concomitant<br />administration of clarithromycin and enzyme inducers.<br />Etravirine<br />Clarithromycin exposure was decreased by etravirine; however, concentrations<br />of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-<br />OH-clarithromycin has reduced activity against Mycobacterium avium<br />complex (MAC), overall activity against this pathogen may be altered;</p><p>therefore alternatives to clarithromycin should be considered for the treatment<br />of MAC.<br />Fluconazole<br />Concomitant administration of fluconazole 200 mg daily and clarithromycin<br />500 mg twice daily to 21 healthy volunteers led to increases in the mean<br />steady-state minimum clarithromycin concentration (Cmin) and area under the<br />curve (AUC) of 33% and 18% respectively. Steady state concentrations of the<br />active metabolite 14-OH-clarithromycin were not significantly affected by<br />concomitant administration of fluconazole. No clarithromycin dose adjustment<br />is necessary.</p><p>Ritonavir<br />A pharmacokinetic study demonstrated that the concomitant administration of<br />ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours<br />resulted in a marked inhibition of the metabolism of clarithromycin. The<br />clarithromycin Cmax increased by 31%, Cmin increased 182% and AUC<br />increased by 77% with concomitant administration of ritonavir. An essentially<br />complete inhibition of the formation of 14-OH-clarithromycin was noted.<br />Because of the large therapeutic window for clarithromycin, no dosage<br />reduction should be necessary in patients with normal renal function.<br />However, for patients with renal impairment, the following dosage<br />adjustments should be considered: For patients with CLCR 30 to 60 mL/min the<br />dose of clarithromycin should be reduced by 50%. For patients with CLCR &lt;30<br />mL/min the dose of clarithromycin should be decreased by 75%. Doses of<br />clarithromycin greater than 1 g/day should not be co-administered with<br />ritonavir.<br />Similar dose adjustments should be considered in patients with reduced renal<br />function when ritonavir is used as a pharmacokinetic enhancer with other HIV<br />protease inhibitors including atazanavir and saquinavir (see section below, Bidirectional<br />drug interactions).</p><p>Effect of Clarithromycin on Other Medicinal Products<br />CYP3A-based interactions<br />Co-administration of clarithromycin, known to inhibit CYP3A, and a drug<br />primarily metabolised by CYP3A may be associated with elevations in drug<br />concentrations that could increase or prolong both therapeutic and adverse<br />effects of the concomitant drug. Clarithromycin should be used with caution in<br />patients receiving treatment with other drugs known to be CYP3A enzyme<br />substrates, especially if the CYP3A substrate has a narrow safety margin (e.g.<br />carbamazepine) and/or the substrate is extensively metabolised by this<br />enzyme.<br />Dosage adjustments may be considered, and when possible, serum<br />concentrations of drugs primarily metabolised by CYP3A should be monitored<br />closely in patients concurrently receiving clarithromycin.</p><p>The following drugs or drug classes are known or suspected to be metabolised<br />by the same CYP3A isozyme: alprazolam, astemizole, carbamazepine,<br />cilostazol, cisapride, ciclosporin, disopyramide, ergot alkaloids, lovastatin,<br />methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g.<br />warfarin, see 4.4), atypical antipsychotics (e.g. quetiapine), pimozide,<br />quinidine, rifabutin, sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine,<br />triazolam and vinblastine but this list is not exhaustive. Drugs interacting by<br />similar mechanisms through other isozymes within the cytochrome P450<br />system include phenytoin, theophylline and valproate.</p><p>Antiarrhythmics<br />There have been post-marketed reports of torsades de pointes occurring with<br />the concurrent use of clarithromycin and quinidine or disopyramide.<br />Electrocardiograms should be monitored for QT prolongation during coadministration<br />of clarithromycin with these drugs. Serum levels of quinidine<br />and disopyramide should be monitored during clarithromycin therapy.<br />There have been post marketing reports of hypoglycemia with the concomitant<br />administration of clarithromycin and disopyramide. Therefore blood glucose<br />levels should be monitored during concomitant administration of<br />clarithromycin and disopyramide.<br />Oral hypoglycemic agents/Insulin<br />With certain hypoglycemic drugs such as nateglinide, and repaglinide,<br />inhibition of CYP3A enzyme by clarithromycin may be involved and could<br />cause hypolgycemia when used concomitantly. Careful monitoring of glucose<br />is recommended.</p><p>Omeprazole<br />Clarithromycin (500 mg every 8 hours) was given in combination with<br />omeprazole (40 mg daily) to healthy adult subjects. The steady-state plasma<br />concentrations of omeprazole were increased (Cmax, AUC0-24, and t1/2 increased<br />by 30%, 89%, and 34%, respectively), by the concomitant administration of<br />clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole<br />was administered alone and 5.7 when omeprazole was co-administered with<br />clarithromycin.<br />Sildenafil, tadalafil and vardenafil<br />Each of these phosphodiesterase inhibitors is metabolised, at least in part, by<br />CYP3A, and CYP3A may be inhibited by concomitantly administered<br />clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil<br />or vardenafil would likely result in increased phosphodiesterase inhibitor<br />exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be<br />considered when these drugs are co-administered with clarithromycin.<br />Theophylline, carbamazepine<br />Results of clinical studies indicate that there was a modest but statistically<br />significant (p&le; 0.05) increase of circulating theophylline or carbamazepine</p><p>levels when either of these drugs were administered concomitantly with<br />clarithromycin. Dose reduction may need to be considered.<br />Tolterodine<br />The primary route of metabolism for tolterodine is via the 2D6 isoform of<br />cytochrome P450 (CYP2D6). However, in a subset of the population devoid of<br />CYP2D6, the identified pathway of metabolism is via CYP3A. In this<br />population subset, inhibition of CYP3A results in significantly higher serum<br />concentrations of tolterodine. A reduction in tolterodine dosage may be<br />necessary in the presence of CYP3A inhibitors, such as clarithromycin in the<br />CYP2D6 poor metaboliser population.<br />Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)<br />When midazolam was co-administered with clarithromycin tablets (500 mg<br />twice daily), midazolam AUC was increased 2.7-fold after intravenous<br />administration of midazolam. If intravenous midazolam is co-administered<br />with clarithromycin, the patient must be closely monitored to allow dose<br />adjustment. Drug delivery of midazolam via oromucosal route, which could<br />bypass pre-systemic elimination of the drug, will likely result in a similar<br />interaction to that observed after intravenous midazolam rather than oral<br />administration. The same precautions should also apply to other<br />benzodiazepines that are metabolised by CYP3A, including triazolam and<br />alprazolam. For benzodiazepines which are not dependent on CYP3A for their<br />elimination (temazepam, nitrazepam, lorazepam), a clinically important<br />interaction with clarithromycin is unlikely.</p><p>There have been post-marketing reports of drug interactions and central<br />nervous system (CNS) effects (e.g., somnolence and confusion) with the<br />concomitant use of clarithromycin and triazolam. Monitoring the patient for<br />increased CNS pharmacological effects is suggested.</p><p>Other drug interactions<br />Colchicine<br />Colchicine is a substrate for both CYP3A and the efflux transporter, Pglycoprotein<br />(Pgp). Clarithromycin and other macrolides are known to inhibit<br />CYP3A and Pgp. When clarithromycin and colchicine are administered<br />together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to<br />increased exposure to colchicine (see section 4.3 and 4.4).<br />Digoxin<br />Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein<br />(Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and<br />digoxin are administered together, inhibition of Pgp by clarithromycin may<br />lead to increased exposure to digoxin. Elevated digoxin serum concentrations<br />in patients receiving clarithromycin and digoxin concomitantly have also been<br />reported in post marketing surveillance. Some patients have shown clinical<br />signs consistent with digoxin toxicity, including potentially fatal arrhythmias.<br />Serum digoxin concentrations should be carefully monitored while patients are<br />receiving digoxin and clarithromycin simultaneously.</p><p>Zidovudine<br />Simultaneous oral administration of clarithromycin tablets and zidovudine to<br />HIV-infected adult patients may result in decreased steady-state zidovudine<br />concentrations. Because clarithromycin appears to interfere with the<br />absorption of simultaneously administered oral zidovudine, this interaction can<br />be largely avoided by staggering the doses of clarithromycin and zidovudine to<br />allow for a 4-hour interval between each medication. This interaction does not<br />appear to occur in paediatric HIV-infected patients taking clarithromycin<br />suspension with zidovudine or dideoxyinosine. This interaction is unlikely<br />when clarithromycin is administered via intravenous infusion.<br />Phenytoin and Valproate<br />There have been spontaneous or published reports of interactions of CYP3A<br />inhibitors, including clarithromycin with drugs not thought to be metabolised<br />by CYP3A (e.g. phenytoin and valproate). Serum level determinations are<br />recommended for these drugs when administered concomitantly with<br />clarithromycin. Increased serum levels have been reported.</p><p>Bi-directional drug interactions<br />Atazanavir<br />Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A,<br />and there is evidence of a bi-directional drug interaction. Co-administration of<br />clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily)<br />resulted in a 2-fold increase in exposure to clarithromycin and a 70% decrease<br />in exposure to 14-OH-clarithromycin, with a 28% increase in the AUC of<br />atazanavir. Because of the large therapeutic window for clarithromycin, no<br />dosage reduction should be necessary in patients with normal renal function.<br />For patients with moderate renal function (creatinine clearance 30 to<br />60 mL/min), the dose of clarithromycin should be decreased by 50%. For<br />patients with creatinine clearance &lt;30 mL/min, the dose of clarithromycin<br />should be decreased by 75% using an appropriate clarithromycin formulation.<br />Doses of clarithromycin greater than 1000 mg per day should not be coadministered<br />with protease inhibitors.</p><p>Calcium Channel Blockers<br />Caution is advised regarding the concomitant administration of clarithromycin<br />and calcium channel blockers metabolized by CYP3A4 (e.g. verapamil,<br />amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations<br />of clarithromycin as well as calcium channel blockers may increase due to the<br />interaction. Hypotension, bradyarrhythmias and lactic acidosis have been<br />observed in patients taking clarithromycin and verapamil concomitantly.<br />Itraconazole<br />Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A,<br />leading to a bidirectional drug interaction. Clarithromycin may increase the<br />plasma levels of itraconazole, while itraconazole may increase the plasma<br />levels of clarithromycin. Patients taking itraconazole and clarithromycin</p><p>concomitantly should be monitored closely for signs or symptoms of increased<br />or prolonged pharmacologic effect.<br />Saquinavir<br />Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A,<br />and there is evidence of a bi-directional drug interaction. Concomitant<br />administration of clarithromycin (500 mg twice daily) and saquinavir (soft<br />gelatin capsules, 1200 mg three times daily) to 12 healthy volunteers resulted<br />in steady-state AUC and Cmax values of saquinavir which were 177% and<br />187% higher than those seen with saquinavir alone. Clarithromycin AUC and<br />Cmax values were approximately 40% higher than those seen with<br />clarithromycin alone. No dose adjustment is required when the two drugs are<br />co-administered for a limited time at the doses/formulations studied.<br />Observations from drug interaction studies using the soft gelatin capsule<br />formulation may not be representative of the effects seen using the saquinavir<br />hard gelatin capsule. Observations from drug interaction studies performed<br />with saquinavir alone may not be representative of the effects seen with<br />saquinavir/ritonavir therapy. When saquinavir is co-administered with<br />ritonavir, consideration should be given to the potential effects of ritonavir on<br />clarithromycin (see section 4.5: Ritonavir).<br />Patients taking oral contraceptives should be warned that if diarrhoea,<br />vomiting or breakthrough bleeding occur there is a possibility of contraceptive</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of clarithromycin for use during pregnancy has not been<br />established. Based on variable results obtained from studies in mice, rats,<br />rabbits and monkeys, the possibility of adverse effects on embryofoetal<br />development cannot be excluded. Therefore, use during pregnancy is not<br />advised without carefully weighing the benefits against risk.<br />Breast-feeding<br />The safety of clarithromycin for using during breast-feeding of infants has not<br />been established. Clarithromycin is excreted into human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use<br />machines. The potential for dizziness, vertigo, confusion and disorientation,<br />which may occur with the medication, should be taken into account before<br />patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile</p><p>The most frequent and common adverse reactions related to clarithromycin<br />therapy for both adult and paediatric populations are abdominal pain,<br />diarrhoea, nausea, vomiting and taste perversion. These adverse reactions are<br />usually mild in intensity and are consistent with the known safety profile of<br />macrolide antibiotics (see section b of section 4.8).<br />There was no significant difference in the incidence of these gastrointestinal<br />adverse reactions during clinical trials between the patient population with or<br />without pre-existing mycobacterial infections.</p><p>b. Tabulated summary of adverse reactions<br />The following table displays adverse reactions reported in clinical trials and<br />from post-marketing experience with clarithromycin immediate-release<br />tablets, granules for oral suspension, powder for solution for injection,<br />extended-release tablets and modified-release tablets.<br />The reactions considered at least possibly related to clarithromycin are<br />displayed by system organ class and frequency using the following<br />convention: very common (&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon<br />(&ge;1/1,000 to &lt; 1/100) and not known (adverse reactions from post-marketing<br />experience; cannot be estimated from the available data). Within each<br />frequency grouping, adverse reactions are presented in order of decreasing<br />seriousness when the seriousness could be assessed.</p><table border="1" cellspacing="1" cellpadding="0" style="width:1083px"><tbody><tr><td><p>System Organ<br />Class</p></td><td><p>Very common<br />&ge;1/10</p></td><td><p>Common<br />&ge; 1/100 to &lt;<br />1/10</p></td><td><p>Uncommon<br />&ge;1/1,000 to &lt; 1/100</p></td><td><p>Not Known*<br />(cannot be estimated from<br />the available data)</p></td></tr><tr><td><p>Infections and<br />infestations</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Cellulitis1, candidiasis,<br />gastroenteritis2,<br />infection3, vaginal<br />infection</p></td><td><p>Pseudomembranous<br />colitis, erysipelas,</p></td></tr><tr><td><p>Blood and<br />lymphatic<br />system</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Leukopenia,<br />neutropenia4,<br />thrombocythaemia3,<br />eosinophilia4</p></td><td><p>Agranulocytosis,<br />thrombocytopenia</p></td></tr><tr><td><p>Immune system<br />disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Anaphylactoid reaction1,<br />hypersensitivity</p></td><td><p>Anaphylactic reaction.<br />angioedema</p></td></tr><tr><td><p>Metabolism and<br />nutrition<br />disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Anorexia, decreased<br />appetite</p></td><td>&nbsp;</td></tr><tr><td><p>Psychiatric<br />disorders</p></td><td>&nbsp;</td><td><p>Insomnia</p></td><td><p>Anxiety, nervousness3,</p></td><td><p>Psychotic disorder,<br />confusional state5,<br />depersonalisation,<br />depression, disorientation,<br />hallucination, abnormal<br />dreams, mania</p></td></tr><tr><td><p>Nervous system<br />disorders</p></td><td>&nbsp;</td><td><p>Dysgeusia,<br />headache</p></td><td><p>Loss of consciousness1,<br />dyskinesia1, dizziness,<br />somnolence5, tremor</p></td><td><p>Convulsion, ageusia,<br />parosmia, anosmia,<br />paraesthesia</p></td></tr><tr><td><p>Ear and<br />labyrinth&nbsp;disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Vertigo, hearing<br />impaired, tinnitus</p></td><td><p>Deafness</p></td></tr><tr><td><p>Cardiac<br />disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Cardiac arrest1, atrial<br />fibrillation1,<br />electrocardiogram QT<br />prolonged,<br />extrasystoles1,<br />palpitations</p></td><td><p>Torsades de pointes,<br />ventricular tachycardia,<br />Ventricular fibrillation</p></td></tr><tr><td><p>Vascular<br />disorders</p></td><td>&nbsp;</td><td><p>Vasodilation1</p></td><td>&nbsp;</td><td><p>Haemorrhage8</p></td></tr><tr><td><p>Respiratory,<br />thoracic and<br />mediastinal<br />disorder</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Asthma1, epistaxis2,<br />pulmonary embolism1</p></td><td>&nbsp;</td></tr><tr><td><p>Gastrointestinal<br />disorders</p></td><td>&nbsp;</td><td><p>Diarrhoea,<br />vomiting,<br />dyspepsia,<br />nausea,<br />abdominal pain</p></td><td><p>Oesophagitis1,<br />gastrooesophageal reflux<br />disease2, gastritis,<br />proctalgia2, stomatitis,<br />glossitis, abdominal<br />distension4, constipation,<br />dry mouth, eructation,<br />flatulence</p></td><td><p>Pancreatitis acute, tongue<br />discolouration, tooth<br />discolouration</p></td></tr><tr><td><p>Hepatobiliary<br />disorders</p></td><td>&nbsp;</td><td><p>Liver function<br />test abnormal</p></td><td><p>Cholestasis4, hepatitis4,<br />alanine aminotransferase<br />increased, aspartate<br />aminotransferase<br />increased, gammaglutamyltransferase<br />increased4</p></td><td><p>Hepatic failure, jaundice<br />hepatocellular</p></td></tr><tr><td><p>Skin and<br />subcutaneous<br />tissue disorders</p></td><td>&nbsp;</td><td><p>Rash,<br />hyperhidrosis</p></td><td><p>Dermatitis bullous1,<br />pruritus, urticaria, rash<br />maculo-papular3</p></td><td><p>Severe cutaneous adverse<br />reactions (SCAR) (e.g.<br />Acute generalised<br />exanthematous pustulosis<br />(AGEP),Stevens-Johnson<br />syndrome, toxic epidermal<br />necrolysis, drug rash with<br />eosinophilia and systemic<br />symptoms (DRESS)), acne</p></td></tr><tr><td><p>Musculoskeleta<br />l and<br />connective<br />tissue disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Muscle spasms3,<br />musculoskeletal<br />stiffness1, myalgia2</p></td><td><p>Rhabdomyolysis2,6,<br />myopathy</p></td></tr><tr><td><p>Renal and<br />urinary<br />disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Blood creatinine<br />increased1, blood urea<br />increased1</p></td><td><p>Renal failure, nephritis<br />interstitial</p></td></tr><tr><td><p>General<br />disorders and<br />administration<br />site conditions</p></td><td><p>Injection site<br />phlebitis1</p></td><td><p>Injection site<br />pain1, injection<br />site<br />inflammation1</p></td><td><p>Malaise4, pyrexia3,<br />asthenia, chest pain4,<br />chills4, fatigue4</p></td><td>&nbsp;</td></tr><tr><td><p>Investigations</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Albumin globulin ratio<br />abnormal1, blood<br />alkaline phosphatase<br />increased4,<br />blood lactate<br />dehydrogenase<br />increased4</p></td><td><p>International normalised<br />ratio increased,<br />prothrombin time<br />prolonged, urine colour<br />abnormal</p></td></tr></tbody></table><p>1 ADRs reported only for the Powder for Concentrate for Solution for Infusion<br />formulation<br />2ADRs reported only for the Extended-Release Tablets formulation</p><p>3 ADRs reported only for the Granules for Oral Suspension formulation<br />4 ADRs reported only for the Immediate-Release Tablets formulation<br />5,6 See section c)<br />* Because these reactions are reported voluntarily from a population of uncertain<br />size, it is not always possible to reliably estimate their frequency or establish a causal<br />relationship to drug exposure. Patient exposure is estimated to be greater than 1<br />billion patient treatment days for clarithromycin.</p><p>c. Description of selected adverse reactions<br />Injection site phlebitis, injection site pain, and injection site inflammation are<br />specific to the clarithromycin intravenous formulation.<br />In some of the reports of rhabdomyolysis, clarithromycin was administered<br />concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3<br />and 4.4).<br />There have been post-marketing reports of drug interactions and central<br />nervous system (CNS) effects (e.g. somnolence and confusion) with the<br />concomitant use of clarithromycin and triazolam. Monitoring the patient for<br />increased CNS pharmacological effects is suggested (see section 4.5).<br />There have been rare reports of clarithromycin ER tablets in the stool, many of<br />which have occurred in patients with anatomic (including ileostomy or<br />colostomy) or functional gastrointestinal disorders with shortened GI transit<br />times. In several reports, tablet residues have occurred in the context of<br />diarrhoea. It is recommended that patients who experience tablet residue in<br />the stool and no improvement in their condition should be switched to a<br />different clarithromycin formulation (e.g. suspension) or another antibiotic.<br />Special population: Adverse Reactions in Immunocompromised Patients (see<br />section e).</p><p>d. Paediatric populations<br />Clinical trials have been conducted using clarithromycin paediatric suspension<br />in children 6 months to 12 years of age. Therefore, children under 12 years of<br />age should use clarithromycin paediatric suspension.<br />Frequency, type and severity of adverse reactions in children are expected to<br />be the same as in adults.</p><p>e. Other special populations<br />Immunocompromised patients<br />In AIDS and other immunocompromised patients treated with the higher doses<br />of clarithromycin over long periods of time for mycobacterial infections, it<br />was often difficult to distinguish adverse events possibly associated with</p><p>clarithromycin administration from underlying signs of Human<br />Immunodeficiency Virus (HIV) disease or intercurrent illness.<br />In adult patients, the most frequently reported adverse reactions by patients<br />treated with total daily doses of 1000 mg and 2000mg of clarithromycin were:<br />nausea, vomiting, taste perversion, abdominal pain, diarrhoea, rash, flatulence,<br />headache, constipation, hearing disturbance, Serum Glutamic Oxaloacetic<br />Transaminase (SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT)<br />elevations. Additional low-frequency events included dyspnoea, insomnia and<br />dry mouth. The incidences were comparable for patients treated with 1000mg<br />and 2000mg, but were generally about 3 to 4 times as frequent for those<br />patients who received total daily doses of 4000mg of clarithromycin.<br />In these immunocompromised patients, evaluations of laboratory values were<br />made by analysing those values outside the seriously abnormal level (i.e. the<br />extreme high or low limit) for the specified test. On the basis of these criteria,<br />about 2% to 3% of those patients who received 1000mg or 2000mg of<br />clarithromycin daily had seriously abnormal elevated levels of SGOT and<br />SGPT, and abnormally low white blood cell and platelet counts. A lower<br />percentage of patients in these two dosage groups also had elevated Blood<br />Urea Nitrogen levels. Slightly higher incidences of abnormal values were<br />noted for patients who received 4000mg daily for all parameters except White<br />Blood Cell.</p><p>To report any side effect(s):<br />-National Pharmacovigilance Center (NPC)<br />o Fax: +966-1-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be<br />expected to produce gastro-intestinal symptoms. One patient who had a<br />history of bipolar disorder ingested 8 grams of clarithromycin and showed<br />altered mental status, paranoid behaviour, hypokalaemia and hypoxaemia.<br />Adverse reactions accompanying overdosage should be treated by the prompt<br />elimination of unabsorbed drug and supportive measures. As with other<br />macrolides, clarithromycin serum levels are not expected to be appreciably<br />affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />ATC Classification:</p><p>Pharmacotherapeutic group: Antibacterial for systemic use, macrolide<br />ATC-Code: J01FA09<br />Mode of Action:<br />Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It<br />exerts its antibacterial action by selectively binding to the 50s ribosomal subunit<br />of susceptible bacteria preventing translocation of activitate amino acids.<br />It inhibits the intracellular protein synthesis of susceptible bacteria.<br />The 14-(R)-hydroxy metabolite of clarithromycin, a product of parent drug<br />metabolism also has antimicrobial activity. The metabolite is less active than<br />the parent compound for most organisms, including mycobacterium spp. An<br />exception is Haemophilus influenza where the 14-hydroxy metabolite is twofold<br />more active than the parent compound.<br />Clarithromycin is usually active against the following organisms in vitro:</p><p>Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible);<br />Streptococcus pyogenes (Group A beta-hemolytic streptococci); alphahemolytic<br />streptococci (viridans group); Streptococcus (Diplococcus)<br />pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.<br />Gram-negative Bacteria: Haemophilus influenza; Haemophilus<br />parainfluenza; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae;<br />Legionella pneumophila; Bordetella pertussis; Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.<br />Other Organisms: Chlamydia trachomatis; Mycobacterium avium;<br />Mycobacterium leprae; Mycobacterium kansasii; Mycobacterium chelonae;<br />Mycobacterium fortuitum; Mycobacterium intracellularis; Chlamydia<br />pneumoniae.<br />Anaerobes: Clostridium perfringens; Peptococcus species;<br />Peptostreptococcus species; Propionibacterium acnes.</p><p>Clarithromycin has bactericidal activity against several bacterial strains. The<br />organisms include Haemophilus influenzae; Streptococcus pneumoniae;<br />Streptococcus pyogenes; Streptococcus agalactiae; Moraxella (Branhamella)<br />catarrhalis; Neisseria gonorrhoeae and Campylobacter spp.<br />Breakpoints<br />The following breakpoints have been established by the European Committee<br />for Antimicrobial Susceptibility Testing (EUCAST).</p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td colspan="3"><p>Breakpoints (MIC, mg/L)</p></td></tr><tr><td><p>Microorganism</p></td><td><p>Susceptible (&le;)</p></td><td><p>Resistant (&gt;)</p></td></tr><tr><td><p>Staphylococcus spp.</p></td><td><p>1 mg/L</p></td><td><p>2 mg/L</p></td></tr><tr><td><p>Streptococcus A, B, C&nbsp;and G</p></td><td><p>0.25 mg/L</p></td><td><p>0.5 mg/L</p></td></tr><tr><td><p>Streptococcus<br />pneumonia</p></td><td><p>0.25 mg/L</p></td><td><p>0.5 mg/L</p></td></tr><tr><td><p>Viridans group<br />streptococcus</p></td><td><p>IE</p></td><td><p>IE</p></td></tr><tr><td><p>Haemophilus spp.</p></td><td><p>1 mg/L</p></td><td><p>32 mg/L</p></td></tr><tr><td><p>Moraxella<br />catarrhalis</p></td><td><p>0.25 mg/L</p></td><td><p>0.5 mg/L 1</p></td></tr><tr><td><p>Helicobacter pylori</p></td><td><p>0.25 mg/L1</p></td><td><p>0.5 mg/L</p></td></tr></tbody></table><p>1 The breakpoints are based on epidemiological cut-off values (ECOFFs),<br />which distinguish wild-type isolates from those with reduces<br />susceptibility.<br />&ldquo;IE&quot; indicates that there is insufficient evidence that the species in<br />question is a good target for therapy with the drug.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The kinetics of orally administered modified-release clarithromycin have been<br />studied in adult humans and compared with clarithromycin 250mg and 500mg<br />immediate release tablets. The extent of absorption was found to be<br />equivalent when equal total daily doses were administered. The absolute<br />bioavailability is approximately 50%. Little or no unpredicted accumulation<br />was found and the metabolic disposition did not change in any species<br />following multiple dosing. Based upon the finding of equivalent absorption<br />the following in vitro and in vivo data are applicable to the modified-release<br />formulation.<br />In vitro: Results of in vitro studies showed that the protein binding of<br />clarithromycin in human plasma averaged about 70 % at concentrations of<br />0.45 - 4.5&mu;g/mL. A decrease in binding to 41% at 45.0&mu;g/mL suggested that<br />the binding sites might become saturated, but this only occurred at<br />concentrations far in excess of therapeutic drug levels.</p><p>In vivo: Clarithromycin levels in all tissues, except the central nervous system,<br />were several times higher than the circulating drug levels. The highest<br />concentrations were found in the liver and lung tissue, where the tissue to<br />plasma ratios reached 10 to 20.<br />The pharmacokinetic behaviour of clarithromycin is non-linear. In fed<br />patients given 500mg clarithromycin modified-release daily, the peak steady<br />state plasma concentration of clarithromycin and 14 hydroxy clarithromycin<br />were 1.3 and 0.48&mu;g/mL, respectively. When the dosage was increased to<br />1000mg daily, these steady-state values were 2.4&mu;g/mL and 0.67&mu;g/mL<br />respectively. Elimination half-lives of the parent drug and metabolite were<br />approximately 5.3 and 7.7 hours respectively. The apparent half-lives of both<br />clarithromycin and its hydroxylated metabolite tended to be longer at higher<br />doses.</p><p>Urinary excretion accounted for approximately 40% of the clarithromycin<br />dose. Faecal elimination accounts for approximately 30%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeated dose studies, clarithromycin toxicity was related to dose and<br />duration of treatment. The primary target organ was the liver in all species,<br />with hepatic lesions seen after 14 days in dogs and monkeys. Systemic<br />exposure levels associated with this toxicity are not known but toxic mg/kg<br />doses were higher than the dose recommended for patient treatment.<br />No evidence of mutagenic potential of clarithromycin was seen during a range<br />of in vitro and in vivo tests.<br />Fertility and reproduction studies in rats have shown no adverse effects.<br />Teratogenicity studies in rats (Wistar (p.o.) and Sprague-Dawley (p.o. and<br />i.v.), New Zealand White rabbits and cynomolgous monkeys failed to<br />demonstrate any teratogenicity from clarithromycin. However, a further<br />similar study in Sprague-Dawley rats indicated a low (6%) incidence of<br />cardiovascular abnormalities which appeared to be due to spontaneous<br />expression of genetic changes. Two mouse studies revealed a variable<br />incidence (3-30%) of cleft palate and in monkeys embryonic loss was seen<br />but only at dose levels which were clearly toxic to the mothers.<br />No other toxicological findings considered to be of relevance to the dose level<br />recommended for patient treatment have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Tablet Core:<br />Citric acid<br />Sodium alginate<br />Sodium calcium alginate<br />Lactose<br />Povidone<br />Talc<br />Stearic acid<br />Magnesium stearate<br />Coating Solution<br />Hypromellose<br />Polyethylene glycol<br />Titanium dioxide<br />Quinoline Yellow (E104 aluminium lake)<br />Sorbic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Store in the original package.<br />Keep this medicine out of sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>7 or 14 tablets in a blister original pack or in bottles. The blisters, of<br />PVC/PVdC, are heat sealed with 20 micron hard tempered aluminium foil and<br />packaged in a cardboard carton with a pack insert.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories Ltd.
Abbott House, Vanwall Business park
Vanwall Road, Maidenhead Berkshire
SL6 4XE, UK
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>